Barcelona-based female-founded VC (est. 2019). 3 funds: €18m Fund I (full), €42m Fund II (full), €50m Fund III (2025). 51+ portfolio companies across 20 countries, 10M+ lives impacted. Team: 23 people, 4 partners incl. founders Dr Marta Zanchi (Stanford Biodesign lead) & Marc Subirats (ex-Teladoc $352M exit). Active investor, hands-on support, strong healthcare expertise.
Investment Focus
Investment Thesis
Specialized pre-seed to Series A health tech VC. Focus: diagnostics, medical devices, clinician training, healthcare infrastructure, clinical pathways. Need-driven founders solving healthcare inefficiencies at intersection of tech+health. Avoids: pharma, vaccines, drugs. Geographic: Pan-Europe, US, Israel, Canada, Australia. Stanford Biodesign-inspired methodology. Active follow-ons; strong value-add on regulatory pathways, healthcare networks, go-to-market. 80%+ Fund I seed graduation rate; Fund II 5x revenue growth.
Interested in connecting?
Visit their website or reach out directly.